The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Sigma Healthcare’s (SIG) Managing Director and Chief Executive Officer, Mark Hooper, has tendered his resignation from the role after over a decade
  • Mark Hooper was first appointed in August 2010 at what the company describes as “a tough time for Sigma”
  • In line with his contract, Hooper has provided six months’ notice, with his departure expected by the end of October 2021
  • The Sigma board will begin its search for a new Chief Executive Officer shortly
  • Sigma shares are down 2.17 per cent, trading at 67.5 cents

After almost eleven years, Mark Hooper has tendered his resignation from the role of Managing Director and Chief Executive Officer of Sigma Healthcare (SIG).

Mark Hooper was first appointed in August 2010, through which time he has led the company through a major restructure following divestment of the pharmaceutical division to Aspen Pharma in 2011 and the acquisitions of CHS, MPS and MIA businesses between 2014 and 2018.

“Our transformation has progressed to plan and has returned Sigma to a position of strength, which creates the ideal opportunity to hand over the leadership to a new CEO,” said Mark Hooper.

“The business is now in great shape, the financial performance is strong, and we have built a platform for sustainable growth over the next few years.”

Hooper also held the role of Chair of the National Pharmaceutical Services Association (NPSA) from October 2015 to August 2020, and guided the company through its imminent implementation of a new enterprise resource planning system.

“Mark became CEO at a tough time for Sigma and put it on a pathway for a stronger future,” said Sigma Chairman Ray Gunston.

“He then undertook the biggest transformation in the company’s history and has set Sigma up for strong earnings growth. I personally, and all of us at Sigma, are very grateful for Mark’s hard work, vision and support over more than 10 years.”

In line with his contract, Hooper has provided six months’ notice, with his departure expected by the end of October 2021.

The Sigma board will begin its search for a new Chief Executive Officer shortly, both internally and externally.

Sigma shares are down 2.17 per cent, trading at 67.5 cents at 12:25 pm AEST. 

SIG by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…